Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 116.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,861 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,541 shares during the period. GAMMA Investing LLC’s holdings in Supernus Pharmaceuticals were worth $90,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Supernus Pharmaceuticals by 2.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company’s stock worth $480,000 after buying an additional 350 shares during the last quarter. Vident Advisory LLC grew its holdings in Supernus Pharmaceuticals by 3.4% during the 1st quarter. Vident Advisory LLC now owns 14,886 shares of the specialty pharmaceutical company’s stock worth $488,000 after acquiring an additional 494 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Supernus Pharmaceuticals by 4.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company’s stock worth $527,000 after purchasing an additional 726 shares during the last quarter. QRG Capital Management Inc. increased its position in shares of Supernus Pharmaceuticals by 5.5% in the 1st quarter. QRG Capital Management Inc. now owns 17,583 shares of the specialty pharmaceutical company’s stock worth $576,000 after purchasing an additional 913 shares during the last quarter. Finally, Financial Management Professionals Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at about $30,000.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $47.96 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $48.64. The stock has a fifty day moving average price of $43.23 and a 200 day moving average price of $36.00. The company has a market cap of $2.69 billion, a P/E ratio of 41.70 and a beta of 0.78.

Analyst Ratings Changes

A number of equities analysts recently commented on SUPN shares. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. Piper Sandler upped their price objective on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a “neutral” rating in a research note on Friday, August 29th. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $51.50.

Insider Activity

In related news, SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $45.87, for a total value of $229,350.00. Following the sale, the senior vice president directly owned 15,496 shares in the company, valued at $710,801.52. This trade represents a 24.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Frederick M. Hudson sold 7,457 shares of the company’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director owned 46,307 shares of the company’s stock, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold 302,841 shares of company stock worth $13,361,449 in the last 90 days. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.